Clinical trial
A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
NCT04594213 is registered in ClinicalTrials.gov with Merz North America, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
- Lead sponsor
- Merz North America, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 23, 2020
- Completion date
- May 9, 2022
- Enrollment
- 362 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
moderate to severe upper facial lines (horizontal forehead lines, glabellar frown lines, and lateral canthal lines)